The Novel Treatment Options For Pulmonary Arterial Hypertension
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Department of Pharmacology and Pharmacotherapy | hu_HU |
| dc.contributor.author | Dahbour, May | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponentdept | Kenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztály | hu_HU |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.date.accessioned | 2021-09-16T11:16:54Z | |
| dc.date.available | 2021-09-16T11:16:54Z | |
| dc.date.created | 2021-05-18 | |
| dc.description.abstract | Pulmonary arterial hypertension is a life threating disease.prior to therapy development the disease mortality was very high and prognosis was poor. Over the last year number of advances in the management of PAH have developed and four new oral medication were approved for the treatment ,this opened the door for new treatment strategies with different modes of medication delivery. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.coursespec | Orvosbiológia-farmakológia | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 72 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/321802 | |
| dc.language.iso | en | hu_HU |
| dc.subject | pulmonary arterial hypertension | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | The Novel Treatment Options For Pulmonary Arterial Hypertension | hu_HU |